STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
2025 Wells Fargo Healthcare Conference
Thursday, September 4, 2025
Boston, MA
Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m. ET
New York, NY
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat Date and Time: Tuesday, September 9, 2025 at 10:30 a.m. ET
New York, NY
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Danielle Jesse
Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Cheryl Wheeler
Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$35.54 |
| Daily Change: | -0.17 -0.48 |
| Daily Volume: | 184,487 |
| Market Cap: | US$1.120B |
August 25, 2025 August 07, 2025 May 08, 2025 March 27, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
